New Horizon Health announced earnings forecast for financial year 2022: total revenue expected to be RMB 766 million, up 260% year-on-year

New Horizon Health recently announced after-hours earnings estimates for FY2022 on the Hong Kong Stock Exchange: As of December 31, 2022, according to unaudited operating data, the Group's FY2022 revenue continued to grow at a high rate of three times and gross margin improved significantly. The hospital channel has become the largest source of revenue and the fastest growing channel for ColoClear, the "No. 1 certificate for early cancer screening in China" product.

For the year ending 31 December 2022, the Group's total revenue is expected to range from CNY 750.5 million to CNY 782.5 million, representing a growth range of 252.7% to 267.7% over the same period in 2021. Total revenue for the year ending 31 December 2021 was CNY 212.8 million.

The Group's annual gross profit for the year ending 31 December 2022 is expected to range from CNY 638.8 million to CNY 656.3 million, representing an increase of 313.2% to 324.5% over the same period in 2021. The Group's annual gross profit for the year ending 31 December 2021 was CNY 154.6 million.

The Company's annual gross profit margin for the year ending December 31 2022, is expected to range from 81.6% to 87.4%, a continued improvement from 2021, when the Group's annual gross profit margin for the year ending December 31, 2021 was 72.7%.

The increase in total revenue and gross profit of the Group was mainly attributable to the increase in revenue and gross profit of ColoClear and Pupu Tube, as well as the launch of a new product, UU Tube, in January 2022.

As of December 31, 2022, the Group's cash balances and specific financial assets are expected to range from CNY 1,571.7 million to CNY 1,573.7 million. As of December 31 2021, the Group's cash balances and specific financial assets were CNY 1,892.1 million. Cash and specific financial assets include bank balances and cash, time deposits of more than three months, structured deposits and pledged bank deposits in the financial statements.

Bioeasy 2022 expected net profit CNY 110 million to CNY 150 million

Recently, Shenzhen Bioeasy Biotechnology released its 2022 annual results forecast. The company expected 2022 annual net profit attributable to shareholders of the listed company to be CNY 110 million to CNY 150 million, down 36.58% to 53.49% year-on-year; Net profit after non-recurring gains and losses of CNY 95 million - CNY 135 million, down 36.83% to 55.54% year-on-year.

Explanation of reasons for changes in performance:

1. During the reporting period, the global epidemic prevention and control stabilized. While the company's Covid-19 related business revenue increases, the orders and revenue of conventional POCT business and food safety inspection business grow. However, due to the implementation of the company's share incentive plan to provide share-based payment expenses; and the global Covid-19 antigen detection products sales unit price decline, the company's Covid-19 products gross profit decline, which has a greater impact on the company's profit in 2022.

2. During the reporting period, the impact of non-recurring gains and losses on the Company's net profit is expected to be approximately CNY 15 million, mainly due to government subsidies and gains from financial management.